- Report
- October 2024
- 180 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- January 2025
- 120 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- August 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- March 2025
- 183 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- May 2024
- 135 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 138 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- April 2023
- 147 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- January 2022
- 105 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Book
- January 2010
- 616 Pages
The Sodium Channel Blocker market is a subset of the Cardiovascular Drugs market. These drugs are used to treat a variety of cardiovascular conditions, including hypertension, angina, and arrhythmias. Sodium Channel Blockers work by blocking the flow of sodium ions through the cell membrane, which helps to reduce the heart rate and blood pressure. These drugs are often used in combination with other medications to treat more severe cardiovascular conditions.
The Sodium Channel Blocker market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. These companies offer a range of products, from generic to branded drugs, to meet the needs of patients. Show Less Read more
